IL2, interleukin 2, 3558

N. diseases: 950; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0003869
Disease: Arthritis, Infectious
Arthritis, Infectious
0.010 Biomarker group BEFREE Impact of simultaneous neutralization of IL-17A and treatment with recombinant IL-2 on Th17-Treg cell population in S.aureus induced septic arthritis. 31790794 2020
CUI: C0010036
Disease: Corneal dystrophy
Corneal dystrophy
0.010 AlteredExpression disease BEFREE Significant higher level of IL-2 was observed in both epithelial and stromal CD. 31756391 2020
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.010 AlteredExpression disease BEFREE IL-2, TNF-<i>α</i>, IL-4, and IL-10 levels were significantly elevated (<i>p</i> < 0.005) in patients with secondary DENV infection, whereas the level of IL-13 remained unaltered during both primary and secondary infections. 31532346 2020
CUI: C0027497
Disease: Nausea
Nausea
0.010 Biomarker phenotype BEFREE Interleukin-2 was elevated after gluten in 97% of patients (median fold-change: 20), and correlated with severity of nausea (r<sub>s</sub>  = .49, P = .0025) and occurrence of vomiting (P = .0005). 31769533 2020
CUI: C0042963
Disease: Vomiting
Vomiting
0.010 Biomarker phenotype BEFREE Interleukin-2 was elevated after gluten in 97% of patients (median fold-change: 20), and correlated with severity of nausea (r<sub>s</sub>  = .49, P = .0025) and occurrence of vomiting (P = .0005). 31769533 2020
CUI: C1692886
Disease: Arthritis, Bacterial
Arthritis, Bacterial
0.010 Biomarker group BEFREE Impact of simultaneous neutralization of IL-17A and treatment with recombinant IL-2 on Th17-Treg cell population in S.aureus induced septic arthritis. 31790794 2020
CUI: C0002874
Disease: Aplastic Anemia
Aplastic Anemia
0.010 AlteredExpression disease BEFREE Among these patients, the IL-2 levels were higher in patients with Very Severe Aplastic Anaemia (VSAA) and Severe Aplastic Anaemia (SAA) than those with Non-severe Aplastic Anaemia (NSAA) in the PBP (65.6 ± 23.61 vs. 31.72 ± 7.64; p-value 0.00338) and (45.37 ± 16.25 vs. 31.72 ± 7.64; p-value 0.01468) respectively. 30139310 2019
CUI: C0003486
Disease: Aortic Aneurysm
Aortic Aneurysm
0.010 AlteredExpression disease BEFREE Considerably increased levels of IL-2 were found in the PBP and BMP of AAA patients as compared to controls (48.54 ± 21.89 vs. 1.99 ± 1.25 p-value < 0.00001) and (75.33 ± 41.9 vs. 3.12 ± 1.82; p-value < 0.00001) respectively. 30139310 2019
CUI: C0003615
Disease: Appendicitis
Appendicitis
0.010 Biomarker disease BEFREE IL-2 and D-dimer values were higher in the groups diagnosed with appendicitis but were not statistically significant. 31290753 2019
CUI: C0007789
Disease: Cerebral Palsy
Cerebral Palsy
0.010 AlteredExpression disease BEFREE In addition, in CP-treated rats, PGE treatment induced the recovery of white blood cell, neutrophil, and lymphocyte counts, along with mid-range absolute counts, and increased the serum levels of inflammatory cytokines (TNF-α, IFN-γ, IL-2, and IL-12) and immunoglobulins (IgG and IgA). 31752816 2019
CUI: C0008707
Disease: Chronic osteomyelitis
Chronic osteomyelitis
0.010 Biomarker disease BEFREE IL-2/STAT5/CD4+CD25+Foxp3 Treg pathway may be involved in the pathogenesis of COM, and excessive immunosuppression may lead to persistent infectious inflammation, which may become a key target for future treatment of COM. 31555698 2019
CUI: C0013274
Disease: Patent ductus arteriosus
Patent ductus arteriosus
0.010 Biomarker disease BEFREE We report that treatment with a novel antibody against tMUC1 in combination with a unique formulation of IL-2 can improve survival and lead to stable disease in appropriate models of PDA by reducing tumor-induced immune regulation and promoting recruitment of CD45+CD11b+ cells, thereby enhancing ADCC/ADCP. 31114758 2019
CUI: C0013473
Disease: Eating Disorders
Eating Disorders
0.010 Biomarker group BEFREE IL-2 increase was not linked to EDs, but to the interaction of depression and BMI. 31450770 2019
CUI: C0014173
Disease: Endometrial Hyperplasia
Endometrial Hyperplasia
0.010 AlteredExpression disease BEFREE Melatonin administration reduced estradiol benzoate-induced endometrial hyperplasia and prevented the occurrence of atypia associated with a significant reduction in lipid peroxide level and NF-κB mRNA and a significant rise in immune-expression of caspase-3, interleukin-2 (IL-2) mRNA and total antioxidant levels in uterine tissues. 30657459 2019
CUI: C0014522
Disease: Epidermodysplasia Verruciformis
Epidermodysplasia Verruciformis
0.010 Biomarker disease BEFREE Inherited Interleukin 2-Inducible T-Cell (ITK) Kinase Deficiency in Siblings With Epidermodysplasia Verruciformis and Hodgkin Lymphoma. 30778533 2019
CUI: C0015230
Disease: Exanthema
Exanthema
0.010 GeneticVariation phenotype BEFREE However, we demonstrated an association between the SNP in IL2 (rs2069762) and the onset of skin rash (P = 0·0001). 30203425 2019
CUI: C0016382
Disease: Flushing
Flushing
0.010 Biomarker phenotype BEFREE <b>Material and Methods</b> In this case control study, after obtaining endometrial flushing fluids at mid-luteal phase of ovulatory women with PCOS (n = 20), endometrioma (n = 19), leiomyoma (n = 20) and healthy controls (n = 20), IL-2 and TNF-α levels were measured using ELISA kits in BioTek ELISA devices. 31148852 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.010 Biomarker disease BEFREE Furthermore, when pretreating ex vivo peripheral blood mononuclear cells of patients with CHF with RvD1 or RvD2, we found that neither of them was able to modulate the immune response of CD8<sup>+</sup> and CD4<sup>+</sup> T cells in terms of proinflammatory cytokine production, namely TNF-α, IFN-γ, IL-17, and IL-2. 30052486 2019
CUI: C0020452
Disease: Hyperemia
Hyperemia
0.010 AlteredExpression disease BEFREE And reduce the degree of edema and hyperaemia around the ulcer tissue significantly (<i>P</i> < 0.01), improve the ulcer healing probability, and reduce the level of TNF-α, VEGF levels and increase IL-2 level in the serum of rats with oral ulcers significantly (<i>P</i> < 0.01). 31049005 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.010 Biomarker group BEFREE Mean arterial pressure was significantly lower in IL-2-treated SLE mice compared with vehicle-treated SLE mice, suggesting that expanding T<sub>REG</sub> cells using low-dose IL-2 attenuates the development of hypertension. 30892934 2019
CUI: C0022104
Disease: Irritable Bowel Syndrome
Irritable Bowel Syndrome
0.010 Biomarker disease BEFREE Subsequently, expression of tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), and IL-6 were detected to further determine the effects of miR-181c-5p and IL1A on inflammation in IBS. miR-181c-5p and IL1A might be involved in IBS. miR-181c-5p was found to be decreased while IL1A was increased in IBS rats. 31172560 2019
CUI: C0024205
Disease: Lymphadenitis
Lymphadenitis
0.010 Biomarker disease BEFREE Mycobacterium avium lysate IL-2 and INF-γ-based enzyme-linked immunospot assays seem to be promising noninvasive diagnostic techniques for discriminating children with nontuberculous mycobacteria lymphadenitis and noninfected subjects. 30834995 2019
Mycobacterium avium-intracellulare Infection
0.010 AlteredExpression disease BEFREE Patients with MAC-LD generally had lower total IFN-γ+, total TNF-α+ and triple-positive T cells but higher mono-IL-2+ expression than the controls and MAC-Co group. 31085455 2019
CUI: C0026946
Disease: Mycoses
Mycoses
0.010 Biomarker group BEFREE The levels of antibodies, including IgM and IgA, cytokines, including IL-2, IL-6, and macrophage colony-stimulating factor (M-CSF), and soluble CD4 and CD8 in the serum of the FI group vs. the control group were determined independently. 31579583 2019
CUI: C0027121
Disease: Myositis
Myositis
0.010 AlteredExpression disease BEFREE At the onset of myositis, the patient lost lower limb mobility against gravity, and had an activated immune profile with increased cytotoxic CD107a and granzyme B expression, as well as pro-inflammatory cytokines, interferon-γ, tumor necrosis factor-α, interleukin-2 in T and NK cells compared to healthy donor. 30604316 2019